AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$MASS

Knopp Kevin J. sold $1.5M of MASS

Knopp Kevin J. (President and CEO) sold 149,013 shares of 908 Devices Inc. (MASS) at an average of $9.90 ($9.06–$10.16, $1.48M total) across 4 trades over 2026-08-10 to 2026-08-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Knopp Kevin J.
Published Aug 12, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MASS
Neutral
high confidence
Mentioned
$MASS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MASSNeutralLow
01

Why it matters

Traders may monitor insider activity for sentiment, but without any new guidance, contract, or operational change, the informational content is limited.

02

Market read

A scheduled CEO sale of about $1.48M worth of MASS shares is disclosed, with no accompanying fundamental news.

03

What to watch

The filing does not state whether sales were part of tax planning, diversification, or option/RSU mechanics beyond the sale code, limiting inference about future performance.

Relevance 5/10Novelty 3/10Timing: Filed on 2026-08-12 after trades dated 2026-08-10 to 2026-08-12

Background

The article is an SEC Form 4 insider transaction disclosure for 908 Devices Inc. (MASS), reported by CEO Kevin J. Knopp.

Company-level read

Ticker impact

$MASSNeutralHigh confidence
Context

SEC Form 4 shows CEO Kevin J. Knopp sold about 149,013 shares of MASS for roughly $1.48M across four trades (10b5-1).

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than earnings or guidance-related.

Evidence & confidence

The article discloses only an open-market sale by the CEO, with explicit 10b5-1 pre-arrangement and no accompanying operational or financial updates.

Market effects

Sector

No sector-level implications are provided; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Issuer
    MASS

    908 Devices Inc., the company whose CEO insider sale is disclosed.

  • Insider
    Kevin J. Knopp

    President and CEO who sold shares via an open-market transaction under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MASS insider trading history →

Related articles

$MASSHigh

908 Devices Inc (MASS) (Q3 2026) Earnings Call Highlights: Record $19 Million Revenue

908 Devices Inc (MASS) reported Q3 2026 revenue of $19M, up 35% YoY, driven by FTIR products and NearLab sales. The company raised full-year revenue guidance to $68.5M-$70M. Adjusted EBITDA loss narrowed to $1.7M, but gross margin decreased to 58%. MASS shipped 300+ devices, bringing the installed base to 4,400. NearLab integration is progressing, with 100 devices sold in Q3. The company remains unprofitable, with a net loss of $4.6M and $2.4M cash burn.

finance.yahoo.com
$MASSMed

908 Devices Q3 2026 slides: 35% growth, raised guidance

908 Devices (NASDAQ:MASS) reported 35% YoY revenue growth to $19.0M in Q3 2026, raising full-year guidance to $68.5M-$70.0M. Shares fell 4.43% premarket. The company focuses on chemical detection tools for public safety and defense, with FTIR products contributing 55% of revenue. Despite narrowing losses, concerns remain over customer concentration and adjusted EBITDA losses.

investing.com
$MASSMed

908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue

908 Devices Inc. (MASS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ 908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue Revenue increased 35% compared to prior year Raises low end of 2026 revenue outlook ​ ​ BURLINGTON, Mass. – November 10, 2026 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap

SEC EDGAR 8-K
$MASSMed

908 Devices Inc. Q2 2026 Earnings Call Summary

908 Devices reported Q2 2026 revenue up 23%, driven by U.S. state and local demand for fentanyl and synthetic drug detection. VipIR saw 35+ shipments, and the NIRLAB acquisition added an AI subscription model. Full-year 2026 revenue guidance was raised to $68m-$70m. Adjusted EBITDA loss narrowed 50% YoY; recurring revenue target is 30%+.

yahoo.com
$MASSMedAI 8/10

908 Devices Q2 Earnings Call Highlights

908 Devices (NASDAQ: MASS) reported Q2 operating expenses of $21.2M, down from $21.5M, and narrowed net loss from continuing operations to $11.9M. Adjusted EBITDA loss improved to $1.9M. Cash and marketable securities were $101.5M with no debt. The company raised 2026 revenue guidance to $68M-$70M and expects recurring revenue of $4.9M (31%).

yahoo.com